Estratificação de risco em linfoma difuso de grandes células B

Hallack Neto, Abrahão E; Pereira, Juliana; Saboya, Rosaura; Beitler, Beatriz; Pracchia, Luis Fernando; Dulley, Frederico L; Chamone, Dalton A. F.
Rev. bras. hematol. hemoter ; 28(4): 296-300, out.-dez. 2006. tab, ilus
Artigo em Português | LILACS | ID: lil-456242

Documentos relacionados

  1. [The biomarkers in medicine: search, choice, study and validation].
  2. Serendipity and margin of safety.
  3. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
  4. The clinical utility of faecal calprotectin in patients with differentiated and undifferentiated spondyloarthritis: Relevance and clinical implications
  5. Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition.
  6. Systems analysis of miRNA biomarkers to inform drug safety.
  7. An evaluation of pharmacogenomic information provided by five common drug information resources.
  8. Nonclinical Development of Biologics: Integrating Safety, Pharmacokinetics, and Pharmacodynamics to Create Smarter and More Flexible Nonclinical Safety Programs Optimizing Animal Use.
  9. How Can We Improve the Use of Established Therapies in PsA?
  10. The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?